J. Ferlay, H. R. Shin, F. Bray, D. Forman, C. Mathers and D. M. Parkin, “GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide,” IARC Cancer Base, Vol. 2, International Agency for Research on Cancer Press, Lyon, 2010. http://globocan.iarc.fr
 A. E. Tammariello and J. A. Milner, “Mouse Models for Unraveling the Importance of Diet in Colon Cancer Prevention,” Journal of Nutritional Biochemistry, Vol. 21, No. 2, 2010, pp. 77-88. doi:10.1016/j.jnutbio.2009.09.014
 D. E. Corpet and F. Pierre, “How Good Are Rodent Models of Carcinogenesis in Predicting Efficacy in Humans? A Systematic Review and Meta-Analysis of Colon Chemoprevention in Rats, Mice and Men,” European Journal of Cancer, Vol. 41, No. 13, 2005, pp. 1911-1922. doi:10.1016/j.ejca.2005.06.006
 M. J. Wargovich, A. Jimenez, K. McKee, et al., “Efficacy of Potential Chemopreventive Agents on Rat Colon Aberrant Crypt Formation and Progression,” Carcinogenesis Vol. 21, No. 6, 2000, pp. 1149-1155. doi:10.1093/carcin/21.6.1149
 M. Per?e and A. Cerar, “Morphological and Molecular Alterations in 1, 2 Dimethylhydrazine and Azoxymethane Induced Colon Carcinogenesis in Rats,” Journal of Biomedicine and Biotechnology, 2011, Article ID: 473964, 14 p.
 H. Jrah Harzallah, B. Kouidhi, et al., “Chemical Composition, Antimicrobial Potential against Cariogenic Bacteria and Cytotoxic Activity of Tunisian Nigella Sativa Essential Oil and Thymoquinone,” Food Chemistry, Vol. 129, No. 4, 2011, pp. 1469-1474. doi:10.1016/j.foodchem.2011.05.117
 H. Gali-Muhtasib, M. Ocker, D. Kuester, et al., “Thymoquinone Reduces Mouse Colon Tumor Cell Invasion and Inhibits Tumor Growth in Murine Colon Cancer Models,” Journal of Cellular and Molecular Medicine, Vol. 12, No. 1, 2008, pp. 330-342. doi:10.1111/j.1582-4934.2007.00095.x
 O. A. Badary and A. M. Gamal El-Din, “Inhibitory Effects of Thymoquinone against 20-Methylcholanthrene-Induced Fibrosarcoma Tumorigenesis,” Cancer Detection and Prevention, Vol. 25, No. 4, 2001, pp. 362-368.
 O. A. Badary, O. A. Al-Shabanah, M. N. Nagi, et al., “Inhibition of Benzo (a) Pyrene-Induced Forestomach Carcinogenesis in Mice by Thymoquinone,” European Journal of Cancer Prevention, Vol. 8, No. 5, 1999, pp. 435-440. doi:10.1097/00008469-199910000-00009
 O. A. Badary, “Thymoquinone Attenuates Ifosfamide-Induced Fanconi syndrome in Rats and Enhances Its Antitumor Activity In mice,” Journal of Ethnopharmacology, Vol. 67, No. 2, 1999, pp. 135-142. doi:10.1016/S0378-8741(98)00242-6
 O. A. Badary, M. N. Nagi, O. A. Al-Shabanah, et al., “Thymoquinone Ameliorates the Nephrotoxicity Induced by Cisplatin in Rodents and Potentiates Its Antitumor Activity,” Canadian Journal of Physiology and Pharmacology, Vol. 75, No. 12, 1997, pp. 1356-1361. doi:10.1139/y97-169
 N. El-Najjar, M. Chatila, H. Moukadem, et al., “Reactive Oxygen Species Mediate Thymoquinone-Induced Apoptosis and Activate ERK and JNK Signaling,” Apoptosis, Vol. 15, No. 2, 2010, pp. 183-195. doi:10.1007/s10495-009-0421-z
 H. Gali-Muhtasib, D. Kuester, C. Mawrin, et al., “Thymoquinone Triggers Inactivation of the Stress Response Pathway Sensor CHEK1 and Contributes to Apoptosis in Colorectal Cancer Cells,” Cancer Research, Vol. 68, No. 14, 2008, pp. 5609-5618.
 M. A. El-Mahdy, Q. Zhu, Q. E. Wang, et al., “Thymoquinone Induces Apoptosis through Activation of Caspase-8 and Mitochondrial Events in p53-Null Myeloblastic Leukemia HL-60 Cells,” International Journal of Cancer, Vol. 117, No. 3, 2005, pp. 409-417. doi:10.1002/ijc.21205
 M. Alhosin, A. Abusnina, M. Achour, et al., “Induction of Apoptosis by Thymoquinone in Lymphoblastic Leukemia Jurkat Cells Is Mediated by a p73-Dependent Pathway Which Targets the Epigenetic Integrator UHRF1,” Biochemical Pharmacology, Vol. 79, No. 9, 2010, pp. 1251-1260.
 L. R. Richards, P. Jones, J. Hughes, et al., “The Physiological Effect of Conventional Treatment with Epigallocatechin-3-Gallate, Thymoquinone, and Tannic Acid on the LNCaP Cell Line,” Biomedical Sciences Instrumentation, Vol. 42, 2006, pp. 357-362.
 N. Chehl, G. Chipitsyna, Q. Gong, et al., “Anti-Inflammatory Effects of the Nigella Sativa Seed Extract, Thzymoquinone, in Pancreatic Cancer Cells,” HPB (Oxford), Vol. 11, 2009, pp. 373-381. doi:10.1111/j.1477-2574.2009.00059.x
 L. R. Richards, P. Jones, H. Benghuzzi, et al., “A Comparison of the Morphological Changes Associated with Conventional and Sustained Treatment with Pigallocatechin3gallate, Thymoquinone, and Tannic Acid on LNCaP Cells,” Biomedical Sciences Instrumentation, Vol. 44, 2008, pp. 465-470.
 A. M. Shoieb, M. Elgayyar, P. S. Dudrick, et al., “In Vitro Inhibition of Growth and Induction of Apoptosis in Cancer Cell Lines by Thymoquinone,” International Journal of Oncology, Vol. 22, No. 1, 2003, pp. 107-113.
 H. Gali-Muhtasib, M. Diab-Assaf, C. Boltze, et al., “Thymoquinone Extracted from Black Seed Triggers Apoptotic Cell Death in Human Colorectal Cancer Cells via a p53-Dependent Mechanism,” International Journal of Oncology, Vol. 25, No. 4, 2004, pp. 857-866.
 D. R. Worthen, O. A. Ghosheh and P. A. Crooks, “The in Vitro Anti-Tumor Activity of Some Crude and Purified Components of Blackseed, Nigella sativa L.,” Anticancer Research, Vol. 18, No. 3A, 1998, pp. 1527-1532.
 H. U. Gali-Muhtasib, W. G. Abou Kheir, L. A. Kheir, et al., “Molecular Pathway for Thymoquinone-Induced Cell-Cycle Arrest and Apoptosis in Neoplastic Keratinocytes,” Anticancer Drugs, Vol. 15, No. 4, 2004, pp. 389-399. doi:10.1097/00001813-200404000-00012
 M. Roepke, A. Diestel, K. Bajbouj, et al., “Lack of p53 Augments Thymoquinone-Induced Apoptosis and Caspase Activation in Human Osteosarcoma Cells,” Cancer Biology & Therapy, Vol. 6, No. 2, 2007, pp. 160-169.
 A. O. Kaseb, K. Chinnakannu, D. Chen, A. Sivanandam, S. Tejwani, M. Menon, et al., “Androgen Receptor and E2F-1 Targeted Thymoquinone Therapy for Hormone-Refractory Prostate Cancer,” Cancer Research, Vol. 67, No. 16, 2007, pp. 7782-7788. doi:10.1158/0008-5472.CAN-07-1483
 T. Yi, S. G. Cho, Z. Yi, X. Pang, M. Rodriguez, Y. Wang, et al., “Thymoquinone Inhibits Tumor Angiogenesis and Tumor Growth through Suppressing AKT and Extracellular Signal-Regulated Kinase Signaling Pathways,” Molecular Cancer Therapeutics, Vol. 7, No. 7, 2008, pp. 1789-1796.
 S. Banerjee, A. O. Kaseb, Z. Wang, D. Kong, M. Mohammad, S. Padhye, et al., “Antitumor Activity of Gemcitabine and Oxaliplatin Is Augmented by Thymoquinone in Pancreatic Cancer,” Cancer Research, Vol. 69, No. 13, 2009, pp. 5575-5583.
 S. Attoub, O. Sperandio, H. Raza, K. Arafat, et al., “Thymoquinone as an Anticancer Agent: Evidence from Inhibition of Cancer Cells Viability and Invasion in Vitro and Tumor Growth in Vivo,” Fundamental & Clinical Pharmacology, 2012. doi:10.1111/j.1472-8206.2012.01056.x
 T. Yi, S. G. Cho, Z. Yi, X. Pang, et al., “Thymoquinone Inhibits Tumor Angiogenesis and Tumor Growth through Suppressing AKT and ERK Signaling Pathways,” Molecular Cancer Therapeutics, Vol. 7, No. 7, 2008, pp. 1789-1796. doi:10.1158/1535-7163.MCT-08-0124
 P. A. Hall, D. A. Levinson and A. L. Woods, “Proliferating Cell Nuclear Antigen (PCNA) Immunolocalization in Paraffin Sections: An Index of Cell Proliferation with Evidence of Deregulated Expression in Some Neoplasm,” Journal of Pathology, Vol. 162, No. 4, 1990, pp. 285-294.
 Y. Zheng, P. M. Kramer, G. Olson, et al., “Prevention by Retinoids of Azoxymethane Induced Tumors and Aberrant Crypt Foci and Their Modulation of Cell Proliferation in the Colon of Rats,” Carcinogenesis, Vol. 18, No. 11, 1997, pp. 2119-2125.
 W. J. Adams, J. A. Lawson, S. E. Nicholson, et al., “The Growth of Carcinogen Induced Colon Cancer in Rats Is Inhibited by Cimetidine,” European Journal of Surgical Oncology, Vol. 19, No. 4, 1993, pp. 332-335.
 B. Shpitz, Y. Bomstein, Y. Mekori, et al., “Proliferating Nuclear Antigen as a Marker of Cell Kinetics in Aberrant Crypt Foci Hyperplastic Polyps, Adenomas, and Adenocarcinomas of the Human Colon,” American Journal of Surgery, Vol. 174, No. 4, 1997, pp. 425-430. doi:10.1016/S0002-9610(97)00122-0
 G. Cohen, R. Mustafi, A. Chumsangsri, et al., “Epidermal Growth Factor Receptor Signaling Is Up-Regulated in Human Colonic Aberrant Crypt Foci,” Cancer Research, Vol. 66, No. 11, 2006, pp. 5656-5664. doi:10.1158/0008-5472.CAN-05-0308
 L. A. Liotta, J. Kleinerman and G. M. Saidel, “Quantitative Relationships of Intravascular Tumor Cells, Tumor Vessels, and Pulmonary Metastases Following Tumor Implantation,” Cancer Research, Vol. 34, 1974, pp. 997-1004.
 G. Gasparini, R. Longo, M. Toi and N. Ferrara, “Angiogenic Inhibitors: A New Therapeutic Strategy in Oncology,” Nature Clinical Practice Oncology, Vol. 2, 2005, pp. 562-577. doi:10.1038/ncponc0342
 M. M. Cooney, W. Van Heeckeren, S. Bhakta, et al., “Drug Insight: Vascular Disrupting Agents and Angiogenesis—Novel Approaches for Drug Delivery,” Nature Clinical Practice Oncology, Vol. 3, 2006, pp. 682-692. doi:10.1038/ncponc0663
 H. N. Fernando and H. I. Hurwitz, “Targeted Therapy of Colorectal Cancer: Clinical Experience with Bevacizumab,” Oncologist, Vol. 9, Suppl. 1, 2004, pp. 11-18. doi:10.1634/theoncologist.9-suppl_1-11
 G. Des Guetz, B. Uzzan, P. Nicolas, et al., “Microvessel Density and VEGF Expression Are Prognostic Factors in Colorectal Cancer. Meta-Analysis of the Literature,” British Journal of Cancer, Vol. 94, No. 12, 2006, pp. 1823-1832. doi:10.1038/sj.bjc.6603176
 Y. Takahashi, Y. Kitadai, C. D. Bucana, et al., “Expression of Vascular Endothelial Growth Factor and Its Receptor, KDR, Correlates with Vascularity, Metastasis, and Proliferation of Human Colon Cancer,” Cancer Research, Vol. 55, No. 18, 1995, pp. 3964-3968.
 K. Werther, I. J. Christensen, N. Brunner and H. J. Nielsen, “Soluble Vascular Endothelial Growth Factor Levels in Patients with Primary Colorectal Carcinoma, The Danish RANX05 Colorectal Cancer Study Group,” European Journal of Surgical Oncology, Vol. 26, No. 7, 2000, pp. 657-662. doi:10.1053/ejso.2000.0977
 K. Werther, I. J. Christensen and H. J. Nielsen, “The Association between Preoperative Concentration of Soluble Vascular Endothelial Growth Factor, Perioperative Blood Transfusion, and Survival in Patients with Primary Colorectal Cancer,” European Journal of Surgery, Vol. 167, No. 4, 2001, pp. 287-292. doi:10.1080/110241501300091480
 K. Werther, I. J. Christensen and H. J. Nielsen, “Prognostic Impact of Matched Preoperative Plasma and Serum VEGF in Patients with Primary Colorectal Carcinoma,” British Journal of Cancer, Vol. 86, No. 3, 2002, pp. 417-423. doi:10.1038/sj.bjc.6600075
 W. S. Tsai, C. R. Changchien, C. Y. Yeh, et al., “Preoperative Plasma Vascular Endothelial Growth Factor but Not Nitrite Is a Useful Complementary Tumor Marker in Patients with Colorectal Cancer,” Diseases of the Colon & Rectum, Vol. 49, No. 6, 2006, pp. 883-894.
 G. Galizia, E. Lieto, F. Ferraraccio, et al., “Determination of Molecular Marker Expression Can Predict Outcome in Colon Carcinomas,” Clinical Cancer Research, Vol. 10, 2004, pp. 3490-3499. doi:10.1158/1078-0432.CCR-0960-03
 K. F. Chin, J. Greenman, E. Gardiner, et al., “Pre-Operative Serum Vascular Endothelial Growth Factor Can Select Patients for Adjuvant Treatment after Curative Resection in Colorectal Cancer,” British Journal of Cancer, Vol. 83, No. 11, 2000, pp. 1425-1431.
 O. Kemik, S. Kemik Ahu, A. Sümer, et al., “Preoperative Vascular Endothelial Growth Factor Levels as a Prognostic Marker for Stage II or III Colorectal Cancer Patients,” Cancer Growth and Metastasis, Vol. 4, 2011, pp. 25-32. doi:10.4137/CGM.S7113
 J. D. Gordan and M. C. Simon, “Hypoxia-Inducible Factors: Central Regulators of the Tumor Phenotype,” Current Opinion in Genetics & Development, Vol. 17, No. 1, 2007, pp. 71-77. doi:10.1016/j.gde.2006.12.006